LinkedIn Image

Transforming Outcomes in Head and Neck Cancer: Immunotherapy Takes Center Stage

Meeting Overview

Engage with the experts at our satellite symposium, Transforming Outcomes in Head and Neck Cancer: Immunotherapy Takes Center Stage, to be held at the American Head and Neck Society (AHNS) 10th International Conference on Head and Neck Cancer in San Diego, California.

This highly interactive educational activity covers topics related to the rationale for targeting the immune system in head and neck squamous cell cancer (HNSCC), the evidence for immune checkpoint inhibitors for recurrent and metastatic HNSCC, and the potential impact of biomarkers on response to immunotherapy. Quiz questions, clinical cases, faculty/participant discussions, audience polling using iPad technology, compelling patient video snippets and prIME Points summarizing key take-away information ensure an engaging learning environment for participants.


06.15 AM Welcome, introduction, and “wake-up quiz”
Ezra Cohen, MD
06.20 AM Why immunotherapy in head and neck cancer?
Andrew Sikora, MD, PhD
06.35 AM Clinical scenario #1 and patient perspective (video clip)
Ezra Cohen, MD
06.40 AM Use of immune checkpoint inhibitors in HNSCC: What have we learned so far?
Robert I. Haddad, MD
06.55 AM Clinical scenario #2 and patient perspective (video clip)
Ezra Cohen, MD
07.00 AM Next steps for immunotherapy in head and neck cancer
Ezra Cohen, MD
07.15 AM Clinical scenarios revisited and audience discussion
Faculty Panel
07.28 AM Conclusion and prIME Points™
Ezra Cohen, MD
07.30 AM Adjourn


  • Ezra Cohen, MDUniversity of California at San Diego
    San Diego, California, United States
  • Robert Haddad, MDDana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Andrew Sikora, MD, PhDBaylor College of Medicine
    Houston, Texas, United States

Target Audience

This educational activity is designed for medical oncologists, radiation oncologists, head and neck surgeons, and other healthcare professionals involved in the treatment of patients with head and neck cancer.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Describe the rationale for targeting the immune system in HNSCC
  • Evaluate efficacy and safety data of immune checkpoint inhibitors in recurrent and metastatic HNSCC and identify patients that may benefit from this treatment
  • Explain unique patterns of response to immuno-oncology agents and management of immune-related adverse events
  • Assess the potential impact of biomarkers such as human papillomavirus (HPV) status, programmed death-ligand 1 (PD-L1), mutational load, and expression profiling on response to immunotherapy
  • Incorporate current and emerging immuno-oncology strategies to multidisciplinary care of head and neck cancer


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Register NowRegister for Live Simulcast

Date and Location

Wednesday, April 26, 2017
6.15 AM – 7.30 AM

Seaport ABC
Manchester Grand Hyatt
1 Market Place
San Diego, California


This activity is provided by prIME Oncology.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.


prIME Oncology designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is supported through an educational grant from Bristol-Myers Squibb.

Sunshine Act

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers. See How Open Payments Works for more information.